Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials. But crucial questions remained unanswered.
Source link : https://www.nytimes.com/2020/12/30/business/china-vaccine.html
Author : Sui-Lee Wee and Amy Qin
Publish date : 2020-12-31 05:16:22
Copyright for syndicated content belongs to the linked Source.
- UNITED KINGDOM
- UNITED STATES